3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 1/2
1
Status
Recruiting
3
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Gastrointestinal
3
Conditions
Carcinoma, Non-Small-Cell Lung
8
Colorectal Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Locally Recurrent Skin Squamous Cell Carcinoma
1
Interventions
Bevacizumab
25
Fluorouracil
23
Leucovorin
22
Cetuximab
22
Oxaliplatin
19
pembrolizumab
14
Specimen Handling
11
Irinotecan
10
Nivolumab
8
Magnetic Resonance Spectroscopy
8
Biopsy
7
atezolizumab
6
fludarabine
5
encorafenib
5
Pemetrexed
5
Panitumumab
5
HMPL-013
5
Gemcitabine
5
Folfox protocol
5
Cisplatin
5
Carboplatin
5
trifluridine tipiracil drug combination
4
balstilimab
4
Standard of Care
4
Immunoglobulin G
4
Disulfides
4
Cyclophosphamide
4
regorafenib
3
fludarabine phosphate
3
dehydroftorafur
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Colorectal Neoplasms
×
amivantamab
×
30 days
×
Clear all
NCT05379595
2026-06-05
OrigAMI-1
Janssen Research & Development, LLC
Phase 1/2
Recruiting
225 enrolled
NCT06662786
2026-06-05
OrigAMI-2
Janssen Research & Development, LLC
Phase 3
Recruiting
1,000 enrolled
NCT06750094
2026-06-05
OrigAMI-3
Janssen Research & Development, LLC
Phase 3
Recruiting
700 enrolled